Form 4: PepGen Inc. Chief Medical Officer Michelle Mellion Reports Stock Transactions

Chief Medical Officer of PepGen Inc., Michelle Mellion, reports the sale and acquisition of common stock and stock options under a pre-arranged Rule 10b5-1 trading plan.

Summary

• Michelle Mellion, Chief Medical Officer of PepGen Inc., filed a Form 4 detailing changes in beneficial ownership.
• On June 24, 2024, Mellion acquired 9,260 shares of common stock through the exercise of stock options at a price of $10.21 per share.
• Simultaneously, Mellion sold 9,260 shares of common stock at a weighted average price of $18.1887 per share, with prices ranging from $18.00 to $18.75.
• These transactions were executed under a Rule 10b5-1 trading plan adopted on January 19, 2024.
• Following these transactions, Mellion's direct ownership of common stock is 0 shares.
• Mellion also holds 80,498 stock options.

Sentiment

Score: 6

Explanation: The sentiment is neutral as the filing reflects routine transactions under a pre-arranged trading plan. There is no indication of positive or negative news about the company's performance.

Positives

• The sale price of $18.1887 is significantly higher than the exercise price of $10.21, indicating a profitable transaction for Mellion.
• The use of a Rule 10b5-1 trading plan suggests that these transactions were pre-planned and not based on insider information.

Negatives

• The sale of shares by a key executive could be perceived negatively by some investors, although the pre-planned nature of the transactions mitigates this concern.

Risks

• There are no specific risks mentioned in this document.
• However, any significant stock sales by key executives could potentially impact investor confidence.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. The use of a 10b5-1 plan is common to avoid accusations of insider trading.

Comparison to Industry Standards

• Form 4 filings are standard practice for publicly traded companies, ensuring transparency in insider trading.
• The use of Rule 10b5-1 trading plans is a common strategy among executives to manage their stock transactions while avoiding potential insider trading concerns, similar to practices seen at companies like Pfizer or Moderna.

Stakeholder Impact

• The transactions may have a minor impact on shareholders, but the pre-planned nature of the transactions should mitigate any significant concerns.

Key Dates